Overview

• The reduction equals roughly 11% of the 78,400-employee workforce, with about 5,000 roles in Denmark.
• The company targets about DKK 8 billion in annualised savings by the end of 2026, with the program starting immediately.
• Novo Nordisk will book an estimated DKK 9 billion one-off restructuring charge in Q3 and expects about DKK 1 billion in savings in Q4.
• Full-year operating profit growth guidance was cut to 4%–10% from 10%–16%, a change the company attributes to restructuring costs.
• Management cites tougher GLP‑1 competition—especially from Eli Lilly—and ongoing pressure from compounded copycat products as key drivers of the overhaul.